BMS-103
BMS-103 is a PDL1 inhibitor (IC50 = 79.1 nM) (kd = 44 nM). BMS-103 reduces the survival rate of acute T-lymphoblastic leukemia cells and ovarian cells. BMS-103 can be used in research on acute T-lymphoblastic leukemia and cancers such as ovarian cancer.
For research use only. We do not sell to patients.
- CAS No.: 1675202-86-4
- Formula: C25H29NO4
- Molecular Weight:407.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Jurkat | IC50 |
5.7 μM
Compound: A1
|
Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 37226718] |
Chemical Information
-
CAS No. 1675202-86-4
-
Molecular Weight 407.50
-
Formula C25H29NO4
-
SMILES
CC1=C(COC2=CC(OC)=C(CNCCO)C(OC)=C2)C=CC=C1C3=CC=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BMS-103 Related Classifications
HY-134778 Related Classifications
Powered by Bioz